Welcome to our featured section on cardiomyopathy

This educational hub pulls together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub will be CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos.

Close X
Other videos you might like

Section Advisor

Professor Perry Elliott

Chair, Cardiovascular Medicine, University College London, and Head, Clinical Research, UCL Institute of Cardiovascular Science, London, UK

Supported through an educational grant from Bristol Myers Squibb.

Recent Videos


Hypertrophic Cardiomyopathy in Review: Highlights from ACC 2021
Iacopo Olivotto


Hypertrophic Cardiomyopathy in Review: Highlights 2019-21
Perry Elliott


ESC 2020: Commentary on the EXPLORER-HCM Study
Giuseppe Galati


ESC 2020 Discussion: The EXPLORER-HCM Study
Harriette Van Spall, Iacopo Olivotto

Video Series

AER: LIVE 2019


VT ablation in non-ischaemic cardiomyopathy
Steve Murray
MiRNAs as biomarkers in hypertrophic cardiomyopathy: current state of the art

Angelopoulos A, Oikonomou E, Vogiatzi G, et al. Curr Med Chem 2021; epub ahead of press.

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

Veselka J, Faber L, Liebregts M, et al. Int J Cardiol 2021;333:127–32.

Ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: treatment strategy, characteristics of consecutive atrial tachycardia and long‐term outcome

Dinshaw L, Münkler P, Schäffer B, et al. J Am Heart Assoc 2021;10:e017451.

Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy?

Cui H, Schaff HV, Dearani JA, et al. J Thorac Cardiovasc Surg 2021;161:997–1006.e3.

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner

Singh RR, McNamara JW, Sadayappan S. J Biol Chem 2021;297:100836.

Prevalence and clinical correlates of aortic dilation in hypertrophic cardiomyopathy

Geske JB, Nordhues BD, Orme NM, et al. J Am Soc Echocardiogr 2021;34:279–85.

Increased heart rate with sleep disordered breathing in hypertrophic cardiomyopathy

Konecny T, Khoo M, Covassin N, et al. Int J Cardiol 2021;323:155–60.

Matrix metalloproteinases increase because of hypoperfusion in obstructive hypertrophic cardiomyopathy

Bi X, Yang C, Song Y, et al. Ann Thorac Surg 2021;111:915–22.

A systematic review of microRNAs in patients with hypertrophic cardiomyopathy

Scolari FL, Faganello LS, Garbin HI, et al. Int J Cardiol 2021;327:146–54.

Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy

Sari M, Erkorkmaz U, Yazar H, et al. Herz 2021;46:164–71.

Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review

Alphonse P, Virk S, Collins J, et al. Clin Res Cardiol 2021;110:544–54.

Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review

Nasser MF, Gandhi S, Siegel RJ, Rader F. Heart Rhythm 2021;18:297–302.

Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction

Sun D, Schaff HV, Nishimura RA, et al. Ann Thorac Surg 2021;111:836–44.

Arrhythmias and conduction disturbances in autoimmune rheumatic disorders

Plastiras SC, Moutsopoulos HM. Arrhythm Electrophysiol Rev 2021;10:17–25.

Coronavirus disease 2019: cardiac complications and considerations for returning to sports participation

Augustine DX, Keteepe-Arachi T, Malhotra A. Eur Cardiol 2021;16:e03.

Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management

Chong DTT, Andreotti F, Verhamme P, et al. Eur Cardiol 2021;16:e23.

Electrocardiographic criteria for differentiating left from right idiopathic outflow tract ventricular arrhythmias

Mariani MV, Piro A, Della Rocca DG, et al. Arrhythm Electrophysiol Rev 2021;10:10–6.

Bridging the gap in a rare cause of angina

Khadke S, Vidovic J, Patel V. Eur Cardiol 2021;16:e05.

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink JR, Diaz R, Felker GM, et al. N Engl J Med 2021;384:105–16.

Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Papadakis M, Basu J, Sharma S. Lancet 2020;396:736–7.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Olivotto I, Oreziak A, Barriales-Villa R, et al. Lancet 2020;396:759–69.

Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction

Rowin EJ, Maron BJ, Carrick RT, et al. J Am Coll Cardiol 2020;75:3033–43.

Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers

Lorenzini M, Norrish G, Field E, et al. J Am Coll Cardiol 2020;76:550–9.

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

Ho CY, Mealiffe ME, Bach RG, et al. J Am Coll Cardiol 2020;75:2649–60.

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry

Neubauer S, Kolm P, Ho CY, et al. J Am Coll Cardiol 2019;74:2333–45.

Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram

Ko WY, Siontis KC, Attia ZI, et al. J Am Coll Cardiol 2020;75:722–33.

Association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement

Bandyopadhyay D, Chakraborty S, Amgai B, et al. JAMA Netw Open 2020;3:e1921669.

Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic

Jabri A, Kalra A, Kumar A, et al. JAMA Netw Open 2020;3:e2014780.

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

Damy T, Garcia-Pavia P, Hanna M, et al. Eur J Heart Fail 2020; epub ahead of press.

Biventricular pacemaker therapy improves exercise capacity in patients with non‐obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise

Ahmed I, Loudon BL, Abozguia K, et al. Eur J Heart Fail 2020;22:1263–72.

Advanced imaging insights in apical hypertrophic cardiomyopathy

Hughes RK, Knott KD, Malcolmson J, et al. JACC Cardiovasc Imaging 2020;13:624–30.

Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study

Pelliccia A, Caselli S, Pelliccia M, et al. Br J Sports Med 2020;54:1008–12.

Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Norrish G, Ding T, Field E, et al. JAMA Cardiol 2019;4:918–27.

Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy

Eberly LA, Day SM, Ashley EA, et al. JAMA Cardiol 2020;5:83–91.

Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population

Lorenzini M, Anastasiou Z, O’Mahony C, et al. JAMA Cardiol 2020;5:73–80.

Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy

Fumagalli C, Maurizi N, Day SM, et al. JAMA Cardiol 2020;5:65–72.

Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance

Fonseca AC, Marto JP, Pimenta D, et al. Neurology 2020;94:e107–13.

Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy

Ho CY, Olivotto I, Jacoby D, et al. Circ Heart Fail 2020;13.

Risk stratification in cardiomyopathy

Sinagra G, Carriere C, Clemenza F, et al. Eur J Prev Cardiol 2020;27:52–8.

Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system

Thomas A, Papoutsidakis N, Spatz E, et al. J Am Heart Assoc 2020;9.

Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy

Liao H, Wang Z, Zhao L, et al. Sci Rep 2020;10:17026.

Left ventricular global function index by magnetic resonance imaging — a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy

Huang S, Xu HY, Diao KY, et al. Sci Rep 2020;10:4707.

Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry

Frommeyer G, Reinke F, Andresen D, et al. Clin Res Cardiol 2020;109:508–12.

Hypertrophic cardiomyopathy - a heterogeneous and lifelong disease in the real world

Kitaoka H, Kubo T, Doi YL. Circ J 2020;84:1218–26.

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy

Geske JB, Driver CN, Yogeswaran V, et al. Am Heart J 2020;221:159–64.

Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy

Lu DY, Ventoulis I, Liu H, et al. Am Heart J 2020;219:58–69.

Update on the diagnostic pitfalls of autopsy and post-mortem genetic testing in cardiomyopathies

Grassi S, Campuzano O, Coll M, et al. Int J Mol Sci 2021;22:4124.

Emerging medical treatment for hypertrophic cardiomyopathy

Argirò A, Zampieri M, Berteotti M, et al. J Clin Med 2021;10:951.

Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy

Zampieri M, Argirò A, Marchi A, et al. Curr Cardiol Rep 2021;23:79.

Catheter Management Of Hypertrophic Cardiomyopathy

Dahal R, Siddiqui T, Adnan G. Catheter Management Of Hypertrophic Cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 May 2.

Differential diagnosis of apical hypertrophic cardiomyopathy and apical displacement of the papillary muscles: a multimodality imaging point of view

Ünlü S, Özden Tok Ö, Avcı Demir F, et al. Echocardiography 2021;38:103–13.

The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review

Sakellaropoulos S, Svab S, Mohammed M, et al. Curr Probl Cardiol 2021;46:100641.

Coronary microvascular dysfunction in hypertrophic cardiomyopathy: pathophysiology, assessment, and clinical impact

Aguiar Rosa S, Rocha Lopes L, Fiarresga A, et al. Microcirculation 2021;28:e12656.

Mitral valve in hypertrophic cardiomyopathy: a three-dimensional transesophageal study

Venieri E, Aggeli C, Anastasakis A, et al. Hellenic J Cardiol 2021;62:29–34.

The regulatory roles of p53 in cardiovascular health and disease

Men H, Cai H, Cheng Q, et al. Cell Mol Life Sci 2021;78:2001–18.


Sundjaja JH, Makaryus AN. Disopyramide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 May 28.

Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy

Ahluwalia M, Ho CY. Heart 2021;107:183–9.

Targeting the population for gene therapy with MYBPC3

Carrier L. J Mol Cell Cardiol 2021;150:101–8.

Calcium Channel Blockers

McKeever RG, Hamilton RJ. Calcium Channel Blockers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2020 Jul 10.

Hypertrophic cardiomyopathy in pregnancy

Saberi S. Cardiol Clin 2021;39:143–50.

Epidemiology of the inherited cardiomyopathies

McKenna WJ, Judge DP. Nat Rev Cardiol 2021;18:22–36.

Hypertrophic Cardiomyopathy

Basit H, Brito D, Sharma S. Hypertrophic Cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Jul 11.

Hypertrophic Cardiomyopathy Overview

Cirino AL, Ho C. Hypertrophic Cardiomyopathy Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. 2008 [updated 2021].

Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis

Chadalawada S, Sillau S, Archuleta S, et al. JAMA Netw Open 2020;3:e2015072.

Contemporary application of cardiovascular magnetic resonance imaging

Han Y, Chen Y, Ferrari VA. Annu Rev Med 2020;71:221–34.

Epsilon waves in biventricular arrythmogenic cardiomyopathy

Lezcano Gort LE, Kounka Z, Roque Rodríguez B. Ann Emerg Med 2020;76:583–5.

Hypertrophic cardiomyopathy: is a 'cure' coming . . . or is it already here?

Maron BJ, Rowin EJ, Maron MS. Am J Med 2020;133:886–8.

Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy

Spoladore R, Fragasso G, Pannone L, et al. Expert Opin Pharmacother 2020;21:233–42.

Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: a systematic review

Chery G, Kamp N, Kosinski AS, et al. Am Heart J 2020;229:52–60.

Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?

European Cardiology Review 2020;15:e11.

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

US Cardiology Review 2019;13(2):74–82.

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Role of T1 Mapping in Inherited Cardiomyopathies

European Cardiology Review 2016;11(2):96–101

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2017;6(2):63–8.

Subclinical Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

US Cardiology Review 2016;10(2):75–7

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes

Arrhythmia & Electrophysiology Review 2016;5(2):90–101

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):188–96

The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):197–202

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy

Interventional Cardiology Review 2014;9(2):108-14

Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies

Arrhythmia & Electrophysiology Review 2013;2(1):36-40

Troponin in Non-ischaemic Dilated Cardiomyopathy

European Cardiology 2011;7(3):220–4

Diagnosis and Management of Cardiomyopathies - A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

European Cardiology 2011;7(3):225–9

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Left Ventricular Non-compaction Cardiomyopathy

American Heart Hospital Journal 2010;8(2):122–4

Myocardial Perfusion Imaging in Hypertrophic Cardiomyopathy

American Heart Hospital Journal 2010;8(2):103–4

Inherited Channelopathies and Cardiomyopathies - When Is Invasive Risk Stratification Needed?

Asia-Pacific Cardiology 2011;3(1):64-6

Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

European Cardiovascular Disease 2007;3(2):88–91

Myocarditis combined with hypertrophic cardiomyopathy: a case report

Wang JY, Wang YS, Shen BT. Ann Palliat Med 2021; epub ahead of press.

A special case of hypertrophic cardiomyopathy with a differential diagnosis of isolated cardiac amyloidosis or junctophilin type 2 associated cardiomyopathy

De Bruijn S, Galloo X, De Keulenaer G, et al. Acta Clin Belg 2021;76:136–43.

Nonobstructive hypertrophic cardiomyopathy in a patient with mitral prosthesis

Sun D, Schaff HV, Gersh BJ, Borlaug BA. Ann Thorac Surg 2021;111:e429–32.

Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmia & Electrophysiology Review 2021;10(1):26–32.


Interventional Cardiology Review 2021;16(Suppl 2):4.

Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome

European Cardiology Review 2019;14(3):191–6

Diagnosis and Therapy of Cardiac Sarcoidosis: A Clinical Perspective

US Cardiology Review 2019;13(1):41–5

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers

US Cardiology Review 2019;13(1):46–8

Chagas Disease and Heart Failure: An Expanding Issue Worldwide

European Cardiology Review 2019;14(2):82–8

Hidden in Heart Failure

European Cardiology Review 2019;14(2):89–96

Preventive Ventricular Tachycardia Ablation in Patients with Ischaemic Cardiomyopathy: Meta-analysis of Randomised Trials

Arrhythmia & Electrophysiology Review 2019;8(3):173–9.

Amyloid Heart Disease

US Cardiology Review 2018;12(2):113–8.

Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

European Cardiology Review 2018;13(2):129.

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

European Cardiology Review 2018;13(2):130.

Premature Ventricular Complex-induced Cardiomyopathy

Arrhythmia & Electrophysiology Review 2018;7(2):128–34.

Arrhythmogenic Inflammatory Cardiomyopathy: A Review

Arrhythmia & Electrophysiology Review 2018;7(3):181–6.

Fulminant Myocarditis: A Review of the Current Literature

US Cardiology Review 2018;12(1):13–6.

Left Ventricular Dysfunction in the Setting of Takotsubo Cardiomyopathy: A Review of Clinical Patterns and Practical Implications

Cardiac Failure Review 2018;4(1):14–20.

Premature Ventricular Contraction-induced Cardiomyopathy

Arrhythmia & Electrophysiology Review 2017;6(4):153–5.

Highlights Of The 2016 European Society Of Cardiology Guidelines On Heart Failure

European Cardiology Review 2017;12(2):76–7

Impact on Patient Care: The 2016 European Heart Failure Guidelines

European Cardiology Review 2017;12(2):78–9

Does Angiotensin Receptor Neprilysin Inhibitor (ARNI) Improve Functional Capacity Assessed by 6 Minutes Walking Test?

European Cardiology Review 2017;12(2):100.

Cardiac Magnetic Resonance in Takotsubo Syndrome

European Cardiology Review 2017;12(1):58–62